Sawai Group Holdings Co Ltd
TSE:4887

Watchlist Manager
Sawai Group Holdings Co Ltd Logo
Sawai Group Holdings Co Ltd
TSE:4887
Watchlist
Price: 2 139 JPY -2.79% Market Closed
Market Cap: 281.2B JPY
Have any thoughts about
Sawai Group Holdings Co Ltd?
Write Note
Sawai Group Holdings Co Ltd
/
Balance Sheet
/
Current Portion of Long-Term Debt

Sawai Group Holdings Co Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sawai Group Holdings Co Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Sawai Group Holdings Co Ltd
TSE:4887
Current Portion of Long-Term Debt
¥4.6B
CAGR 3-Years
-4%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Takeda Pharmaceutical Co Ltd
TSE:4502
Current Portion of Long-Term Debt
¥624.1B
CAGR 3-Years
43%
CAGR 5-Years
29%
CAGR 10-Years
14%
Daiichi Sankyo Co Ltd
TSE:4568
Current Portion of Long-Term Debt
¥400m
CAGR 3-Years
-73%
CAGR 5-Years
-60%
CAGR 10-Years
-43%
Otsuka Holdings Co Ltd
TSE:4578
Current Portion of Long-Term Debt
¥191.2B
CAGR 3-Years
57%
CAGR 5-Years
20%
CAGR 10-Years
9%
Chugai Pharmaceutical Co Ltd
TSE:4519
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Current Portion of Long-Term Debt
¥307.3B
CAGR 3-Years
43%
CAGR 5-Years
47%
CAGR 10-Years
45%
No Stocks Found

Sawai Group Holdings Co Ltd
Glance View

Market Cap
265.2B JPY
Industry
Pharmaceuticals

Sawai Group Holdings Co., Ltd. stands as a prominent figure in the pharmaceutical landscape of Japan and beyond, rooted in a steadfast commitment to produce affordable generic medicines. Originating from humble beginnings in 1929, Sawai has evolved into a formidable player in the industry, underpinned by a strategy that blends innovation with an intricate understanding of healthcare needs. Known for its sharp focus on generic pharmaceutical products, the company has carved a niche by prioritizing the development and manufacture of high-quality, cost-efficient medications. This strategic orientation not only aligns with global healthcare trends but also meets the burgeoning demands of an aging population, both domestically and internationally. Central to Sawai's business model is their vertically integrated operation, covering everything from research and development to manufacturing and distribution. This comprehensive approach allows Sawai to maintain strict control over product quality while maximizing operational efficiency. Revenue flows from its diverse product portfolio, which includes a vast array of therapeutic areas such as cardiovascular, digestive, and central nervous system drugs. Moreover, Sawai's expansion into international markets, particularly in the United States through its subsidiary Upsher-Smith Laboratories, broadens its revenue base. By leveraging strategic acquisitions and partnerships, the company continues to fortify its presence on the global stage, all while steadfastly delivering on its promise of making healthcare accessible and affordable.

Intrinsic Value
2 890.58 JPY
Undervaluation 26%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Sawai Group Holdings Co Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
4.6B JPY

Based on the financial report for Mar 31, 2024, Sawai Group Holdings Co Ltd's Current Portion of Long-Term Debt amounts to 4.6B JPY.

What is Sawai Group Holdings Co Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
-3%

Over the last year, the Current Portion of Long-Term Debt growth was 2%. The average annual Current Portion of Long-Term Debt growth rates for Sawai Group Holdings Co Ltd have been -4% over the past three years , -3% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.